Cellectar reports durable responses to iopofosine I 131 in Phase 2b Waldenström macroglobulinemia trial

Bitget2026/11/04 14:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cellectar Biosciences will present three iopofosine I 131 posters in Waldenström macroglobulinemia at the American Society of Hematology meeting December 12-15, 2026.
Updated Phase 2b CLOVER WaM results show durable responses in heavily pretreated patients, with longer-lasting responses following only two prior treatment lines.
A Phase 3 confirmatory trial will compare iopofosine I 131 with rituximab-cyclophosphamide-dexamethasone in patients previously treated with a Bruton tyrosine kinase inhibitor.
First patient dosing remains targeted for the first quarter of 2027; an FDA filing seeking accelerated approval remains planned for the first half.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9869815) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cellectar reports durable responses to iopofosine I 131 in Phase 2b Waldenström macroglobulinemia trial

You may also like

Crypto prices